Repurposing the Antidiabetic Drugs Glyburide, Gliquidone, and Glipizide in Combination with Benznidazole for <i>Trypanosoma cruzi</i> Infection
Infection with the protozoan parasite <i>Trypanosoma cruzi</i> causes human Chagas disease. Benznidazole (BNZ) and nifurtimox are the current drugs for the treatment; however, they induce severe adverse side effects in patients; therefore, there is a need to improve the treatment effecti...
Saved in:
| Main Authors: | Citlali Vázquez, Rusely Encalada, Isabel Jiménez-Galicia, Rogelio Gómez-Escobedo, Gildardo Rivera, Benjamín Nogueda-Torres, Emma Saavedra |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/21 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The potential of the antifungal nystatin to be repurposed to fight the protozoan Trypanosoma cruzi
by: Belén Jesús Maciel, et al.
Published: (2025-03-01) -
Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysisResearch in context
by: Anis Rassi, Jr, et al.
Published: (2025-01-01) -
Design and Synthesis of Bis-Chalcones as Curcumin Simplified Analogs and Assessment of Their Antiproliferative Activities Against Human Lung Cancer Cells and <i>Trypanosoma cruzi</i> Amastigotes
by: Gabriela Alves de Souza, et al.
Published: (2025-03-01) -
Chagas disease induces gut microbial metabolic stress: Disruption of energy and nucleotide pathways and partial reversal by antiparasitic therapy (TRIPOBIOME-2 study)
by: José A. Pérez-Molina, et al.
Published: (2025-09-01) -
Chagas Disease in a Non-Endemic Setting: Clinical Profile, Treatment Outcomes, and Predictors of Cure in a 15-Year Cohort Study
by: Carlos Bea-Serrano, et al.
Published: (2025-06-01)